EGFR and neuroblastoma: For instance, rhabdomyosarcoma developed resistance against the IGF-1R inhibitor NVP-AEW541 by overexpression of ErbB2 receptor [32], whereas the EGFR specific inhibitors gefitinib, erlotinib or tyrphostin B46 was shown to be ineffective in the treatment of neuroblastoma despite the fact that neuroblastoma expresses high levels of EGFR [33], [34].